Abstract
Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of Lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).
| Original language | English (US) |
|---|---|
| Pages (from-to) | 48-56 |
| Number of pages | 9 |
| Journal | Current Opinion in Lipidology |
| Volume | 6 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1995 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Diet and drug therapy for lipoprotein (a). / Berglund, Lars.
In: Current Opinion in Lipidology, Vol. 6, No. 1, 1995, p. 48-56.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Diet and drug therapy for lipoprotein (a)
AU - Berglund, Lars
PY - 1995
Y1 - 1995
N2 - Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of Lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).
AB - Lipoprotein (a) has been implicated with an increased risk of atherosclerosis and cardiovascular disease. Recently, considerable progress has been made toward understanding the importance of genetics in the regulation of plasma levels of lipoprotein (a). However, the issue as to whether lipoprotein (a) levels should be treated is still debated and furthermore the possibilities to influence lipoprotein (a) levels remain limited. The potential clinical importance of Lipoprotein (a) has stimulated interest in the dietary and pharmacologic agents that affect this lipoprotein. At present, only a few of the existing therapeutic tools, such as nicotinic acid and estrogens, have been found to consistently affect lipoprotein (a).
UR - http://www.scopus.com/inward/record.url?scp=0028942016&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028942016&partnerID=8YFLogxK
U2 - 10.1097/00041433-199502000-00011
DO - 10.1097/00041433-199502000-00011
M3 - Article
C2 - 7735716
AN - SCOPUS:0028942016
VL - 6
SP - 48
EP - 56
JO - Current Opinion in Lipidology
JF - Current Opinion in Lipidology
SN - 0957-9672
IS - 1
ER -